Vanda Pharmaceuticals (VNDA) Stock Rating Upgraded by ValuEngine

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

VNDA has been the topic of several other research reports. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Friday, April 20th. BidaskClub cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 27th. Oppenheimer set a $27.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 5th. Jefferies Group reiterated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. Finally, Seaport Global Securities initiated coverage on shares of Vanda Pharmaceuticals in a report on Friday, January 19th. They issued a “buy” rating and a $20.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.50.

Shares of Vanda Pharmaceuticals opened at $16.65 on Friday, according to MarketBeat.com. The company has a market capitalization of $852.01 million, a PE ratio of -47.57 and a beta of 1.12. Vanda Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $16.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.23. The company had revenue of $43.59 million for the quarter, compared to analysts’ expectations of $43.30 million. Vanda Pharmaceuticals had a negative net margin of 2.84% and a negative return on equity of 3.06%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.11) EPS. research analysts expect that Vanda Pharmaceuticals will post -0.05 earnings per share for the current fiscal year.

In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 8,532 shares of the firm’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $18.72, for a total value of $159,719.04. Following the completion of the transaction, the chief financial officer now directly owns 208,066 shares in the company, valued at $3,894,995.52. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Gunther Birznieks sold 8,525 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total transaction of $159,588.00. Following the completion of the transaction, the senior vice president now owns 148,366 shares of the company’s stock, valued at $2,777,411.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,023 shares of company stock valued at $1,460,591. Corporate insiders own 7.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in VNDA. Armistice Capital LLC boosted its holdings in shares of Vanda Pharmaceuticals by 74.8% during the fourth quarter. Armistice Capital LLC now owns 2,678,000 shares of the biopharmaceutical company’s stock worth $40,706,000 after purchasing an additional 1,146,000 shares during the period. Stonepine Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 195.0% during the fourth quarter. Stonepine Capital Management LLC now owns 885,000 shares of the biopharmaceutical company’s stock worth $13,452,000 after purchasing an additional 585,000 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Vanda Pharmaceuticals by 20.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock worth $34,484,000 after purchasing an additional 378,606 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Vanda Pharmaceuticals by 17.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,434,850 shares of the biopharmaceutical company’s stock worth $21,810,000 after purchasing an additional 216,600 shares during the period. Finally, Alambic Investment Management L.P. acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $3,116,000. Institutional investors own 78.54% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply